Inhibitors cancer

Shenolikar, S. Protein phosphatase regulation by endogenous inhibitors. Cancer Biol. 6 219-227,1995. 

Inhibition of Metastasis by Protease Inhibitors. Cancer metastasis can be inhibited by either synthetic or naturally occurring protease inhibitors. Thus, various synthetic inhibitors of serine proteases have been found to prevent tumor cell invasion through amniotic membranes in vitro and to inhibit cancer metastasis in vivo [for reviews, see Aznavoorian et al. (A4) and Duffy (D6). In... 

Dl. DeClerck, Y. A., Yean, T. D., Chan, D., Shimada, H., and Lansley, K. E., Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor. Cancer Res. 51, 2151-2157 (1991). 

Zhang W, Law RE, Hinton DR, Couldwell WT. (1997). Inhibition of human malignant glioma cell motility and invasion in vitro by hypericin, a potent protein kinase C inhibitor. Cancer Lett. 120(1) 31-8. 

Terui T, Murakami K, Takimoto R, Takahashi M, Takada K, Murakami T, Minami S, Matsunaga T, Takayama T, Kato J, Niitsu Y. (2003) Induction of P1G3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic ceU death by histone deacetylase inhibitors. Cancer Res 63 8948-8954. 

Kishi K, Petersen S, Petersen C, et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000 60 1326-1331. 

Lobell RB, Kohl NE. Pre-clinical development of famesyltransferase inhibitors. Cancer Metastasis Rev 1998 17 203-210. 

Schlaeppi JM, Wood JM. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine kinase inhibitors. Cancer Metastasis Rev 1999 18 4734-81. 

Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000 60 1306-1311. 

Wang W, Marsh S, Cassidy J et al. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res 2001 61 5505-5510. 

Wang SE, Narasanna A, Perez-Torres M et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006 10 25-38. 

Kimura S, Niwa T, Hirabayashi K et al. Development of NS-187, a potent and selective dual BCR-ABL/LYN tyrosine kinase inhibitor. Cancer Chemother Pharmacol 2006,5 , Suppl 7 55-61. 

Peek RM, Jr. Prevention of colorectal cancer through the use of COX-2 selective inhibitors. Cancer Chemoth-er Pharmacol. 2004 54(suppl 1) S50-S56. 

Afshari, C., S. Kodama, H. Bivins, T.B. Willard, H. Fujiki, and J.C. Barrett. 1993. Induction of neoplastic progression in Syrian hamster embryo cells treated with protein phosphatase inhibitors. Cancer Res. 53 1777-1782. 

Klumpen HJ et al (2011) Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev 37(4) 251-260... 

Iurisci, I Filipski, E., Reinhardt, J., Bach, S., Gianella-Borradori, A., Iacobelli, S., Meijer, L., Levi, F. Improved tumor control through circadian clock induction by seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res. 2007, in press. 

Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y (1983) Potentiation of Vincristine and Adriamycin Effects in Human Hemopoietic Tumor Cell Lines by Calcium Antagonists and Calmodulin Inhibitors. Cancer Res 43 2267-2276... 

Eujiki, H., Suganuma, M., Komori, A., Yatsunami, J, Okabe, S., Ohta, T, and Sueoka, E. 1994. A new tumor promotion pathway and its inhibitors. Cancer Detect Prev 18, 1-7. 

Omer, C.A., Chen, Z., Diehl, R.E., Conner, M.W., Chen, H.Y., Trumbauer, M.E., Gopal-Truter, S., Seeburger, G., Bhimnathwala, H., Abrams, M.T., Davide, J.P., EUis, M.S., et al. (2000). Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyhprotein transferase inhibitor. Cancer Res 60 2680-2688. 

Omer, C.A., et at. (2000). Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl protein transferase inhibitor. Cancer Res 60 2680-2688. 

Zi, X. et al., A flavonoid antioxidant, silymarin, inhibits activation of erbBl signaling induces cyclin-dependent kinase inhibitors. Cancer Res., 58, 1920, 1998. 

Rao, C.V., Cooma, I., Simi, B., Maiming, P.T., Connor, J.R. and Reddy, B.S., Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res., 62, 165, 2002. 

Mayer RD, Lee KE, and Cockett AT. Inhibition of cisplatin-induced nephrotoxicity in rats by buthionine sulfoximine, a glutathione synthesis inhibitor. Cancer Chemotherapy and Pharmacology 20 207-210,1987. 

Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer. 2006 107(6) 1207-1218. 

Rose WC, Lee FY, Fairchild CR, Lynch M, Monticello T, et al. 2001. Preclini-cal antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltrans-ferase inhibitor. Cancer Res. 61 7507-17... 

Carvajal D, Tovar C, Yang H et al (2005) Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 65 1918-1924... 

Hong, S. H., Avis, L, Vos, M. D., Martinez, A., Treston, A. M., and Mulshine, J. L. 1999. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res. 59 2223-28. 

Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV. Tumor growth inhibition induced in a murine model of human Burkitt s lymphoma by a proteasome inhibitor. Cancer Res 1998 58 4342-4348. 

Zhuang, Y, et al. (2006). Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor. Cancer Research, 66 (23), 11305-11313. 

L.W. Ma, K. Berg, H.E. Danielsen, O. Kaalhus, V. lani, J. Moan (1996). Enhanced antitumor effect of photodynamic therapy by microtubule inhibitors. Cancer Lett., 109, 129-139. 

P.S. Ebert, I. Wars, D.N. Buell (1976). Erythroid differentiation in cultured Friend leukemia cells treated with metabolic inhibitors. Cancer Res., 36, 1809-1813. 

Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel famesyltransferase inhibitor. Cancer Res. 61 1507-1511. 

Afshari, C.A. and Barrett, J.C., Disruption of Gg-Gj arrest in quiescent and senescent cells treated with phosphatase inhibitors. Cancer Res., 54, 2317, 1994. 

Lai, G., Ash, C., Hay, K., Redston, M., Kwong, E., Hancock, B. et al.. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor. Cancer Res., 61,6131-6136,2001. 

---